CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH | MicrobiomeTrials← Back to trialsNCT06947460
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-04-18Est. Completion: 2026-07-31
Enrollment target: 45 participants Locations- 北京高博医院, Beijing, China,Beijing, China
Other microbiome trials you might be interested in
Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refrac…
Scottsdale, United StatesEst. completion Aug 6, 2028
Rheumatoid Arthritis (RA)Systemic Lupus Erthematosus (SLE)Dermatomyositis (DM)Systemic Sclerosis (SSc)
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, …
Boston, United States
Est. completion Mar 2030